Clopidogrel Tablet, Film Coated
Product Images NDC 68071-3319

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68071-3319). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3319 9 (2)

Clopidogrel 75 mg tablets film coated, bottle label by NuCare Pharmaceuticals, Inc. The label indicates each tablet contains 97.875 mg Clopidogrel Bisulfate USP equivalent to 75 mg Clopidogrel base. Package contains 90 tablets. NDC 68071-3319-9, prescription only. Storage instructions specify controlled temperature 68-77°F.*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal bar graph showing the effect of different proton pump inhibitors (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) on the active metabolite AUC of Clopidogrel Bisulfate 75 mg. The x-axis represents the change relative to Clopidogrel Bisulfate administered alone, ranging from 0.4 to 1.4, with bars indicating mean values and 90% confidence intervals for each PPI.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph showing cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. The graph compares two groups: one receiving placebo plus aspirin and another receiving Clopidogrel Bisulfate plus aspirin, with lower cumulative event rates observed in the Clopidogrel group. A p-value is indicated, denoting statistical significance.*

FDA Label Image

Figure 3: Hazard Ratio For Patient Baseline Characteristics And On-study Concomitant Medications/interventions For The Cure Study (Clopidogrel Fig3)

A forest plot depicting hazard ratios with 95% confidence intervals comparing Clopidogrel Bisulfate versus placebo across various subgroups, including age, gender, race, comorbidities, medication use, and overall population. The chart shows point estimates and confidence intervals to illustrate favorability toward Clopidogrel Bisulfate or placebo for each subgroup.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A Kaplan-Meier survival curve chart comparing the percentage of deaths before first discharge between placebo and Clopidogrel groups over 28 days since randomization. The x-axis shows days, and the y-axis shows percent dead before discharge. Clopidogrel group shows a lower mortality percentage than placebo, with a note of 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A line graph showing the percentage of patients with death, re-infarction, or stroke before first discharge over days since randomization (up to 28 days). Two lines compare outcomes for placebo and Clopidogrel, indicating a 9% proportional risk reduction in the Clopidogrel group.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart showing odds ratios and 99% confidence intervals comparing Clopidogrel Bisulfate versus placebo across various subgroups, including gender, age at entry, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent administration. The chart visualizes whether each subgroup favors Clopidogrel Bisulfate or placebo based on odds ratio values.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph comparing the cumulative event rate (%) of fatal or non-fatal vascular events between aspirin and clopidogrel bisulfate over 36 months of follow-up. The graph shows two lines labeled for aspirin and clopidogrel bisulfate, with cumulative event rates increasing over time. A p-value of 0.045 is indicated, suggesting statistical comparison between the groups.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A forest plot chart displaying hazard ratios with 95% confidence intervals for clinical outcomes comparing Clopidogrel Bisulfate and Aspirin. The chart shows data for qualifying conditions including Stroke, MI, PAD, and Overall population, with numerical values for patient counts and percentages. The hazard ratio scale ranges from 0.6 to 1.3, indicating areas favoring either Clopidogrel Bisulfate or Aspirin.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure diagram of Clopidogrel Bisulfate showing its molecular arrangement including rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.